Bortezomib induces autophagic death in proliferating human endothelial cells

Experimental Cell Research

Volumn 316, Issue 6, 2010, Pages 1010-1018

  Belloni, Daniela ^a   Veschini, Lorenzo ^a   Foglieni, Chiara ^a   Dell'Antonio, Giacomo ^a   Caligaris Cappio, Federico ^a,b   Ferrarini, Marina ^a   Ferrero, Elisabetta ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Antiangiogenesis; Apoptosis; Autophagy; Bortezomib; Endothelial cells

Indexed keywords

BORTEZOMIB; CASPASE 3; FIBROBLAST GROWTH FACTOR; LIPOCORTIN 5; REACTIVE OXYGEN METABOLITE;

ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CELL PROLIFERATION; CELL SHAPE; CELL ULTRASTRUCTURE; CELL VACUOLE; CELL VIABILITY; CHROMATIN CONDENSATION; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MYELOMA CELL; OXIDATIVE STRESS; PHAGOSOME; PRIORITY JOURNAL;

EID: 77649185396     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2009.11.005     Document Type: Article

References (44)

1. Hayden P.J., Mitsiades C.S., Anderson K.C., and Richardson P.G. Novel therapies in myeloma. Curr. Opin. Hematol. 14 (2007) 609-615
2. Yang Y., Kitagaki J., Dai R.M., Tsai Y.C., Lorick K.L., Ludwig R.L., Pierre S.A., Jensen J.P., Davydov I.V., Oberoi P., Li C.C., Kenten J.H., Beutler J.A., Vousden K.H., and Weissman A.M. Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics. Cancer Res. 19 (2007) 9472-9481
3. Chauhan D., Hideshima T., and Anderson K.C. Proteasome inhibition in multiple myeloma: therapeutic implication. Annu. Rev. Pharmacol. Toxicol. 45 (2005) 465-476
4. Richardson P.G., Sonneveld P., Schuster M.W., Irwin D., Stadtmauer E.A., Facon T., Harousseau J.L., Ben-Yehuda D., Lonial S., Goldschmidt H., Reece D., San-Miguel J.F., Bladé J., Boccadoro M., Cavenagh J., Dalton W.S., Boral A.L., Esseltine D.L., Porter J.B., Schenkein D., and Anderson K.C. Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. New Engl. J. Med. 352 (2005) 2487-2498
5. Roccaro A.M., Hideshima T., Raje N., Kumar S., Ishitsuka K., Yasui H., Shiraishi N., Ribatti D., Nico B., Vacca A., Dammacco F., Richardson P.G., and Anderson K.C. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res. 66 (2006) 184-1391
6. Giuliani N., Colla S., and Rizzoli V. Angiogenic switch in multiple myeloma. Hematology 9 (2004) 377-381
7. Pellegrino A., Ria R., Di Pietro G., Citrulli T., Surico G., Pennisi A., Morabito F., Ribatti D., and Vacca A. Bone marrow endothelial cells in multiple myeloma secrete CXC-chemokines that mediate interactions with plasma cells. Br. J. Haematol. 129 (2005) 248-256
8. Veschini L., Belloni D., Foglieni C., Cangi M.G., Ferrarini M., Caligaris-Cappio F., and Ferrero E. Hypoxia-inducible transcription factor-1 alpha determines sensitivity of endothelial cells to the proteosome inhibitor bortezomib. Blood 109 (2007) 2565-2570
9. Cohen J.J. Apoptosis. Immunol. Today 14 (1993) 126-130
10. Nagata S. Fas ligand-induced apoptosis. Ann. Rev. Gen. 33 (1999) 29-55
11. Krammer P.H., Arnold R., and Lavrik I.N. Life and death in peripheral T cells. Nat. Rev. Immunol. 7 (2007) 532-542
12. Chipuk J.E., and Green D.R. How do BCL-2 proteins induce mitochondrial outer membrane permeabilization?. Trends Cell Biol. 18 (2008) 157-164
13. Strasser A., O'Connor L., and Dixit V.M. Apoptosis signaling. Ann. Rev. Biochem. 69 (2000) 217-245
14. Nguyen T.M.B., Subramanian I.V., Kelekar A., and Ramakrishnan S. Kringle 5 of human plasminogen, an angiogenesis inhibitor, induces both autophagy and apoptotic death in endothelial cells. Blood 109 (2007) 4793-4802
15. Gozuacik D., and Kimchi A. Autophagy as a cell death and tumor suppressor mechanism. Oncogene 23 (2004) 2891-2906
16. Kroemer G., and Jäättelä M. Lysosomes and autophagy in cell death control. Nat. Rev. Cancer 5 (2005) 886-897
17. González-Polo R.A., Boya P., Pauleau A.L., Jalil A., Larochette N., Souquère S., Eskelinen E.L., Pierron G., Saftig P., and Kroemer G. The apoptosis/autophagy paradox: autophagic vacuolization before apoptotic death. J. Cell Sci. 118 (2005) 3091-3102
18. Lum J.J., Bauer D.E., Kong M., Harris M.H., Li C., Lindsten T., and Thompson C.B. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 120 (2005) 237-248
19. Claesson-Welsh L., Welsh M., Ito N., Anand-Apte B., Soker S., Zetter B., O'Reilly M., and Folkman J. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 5579-5583
20. Guo N., Krutzsch H.C., Inman K., and Roberts D.D. Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res. 5 (1997) 1735-1742
21. Chau Y.P., Lin S.Y., Chen J.H.C., and Tai M.H. Endostatin induces autophagic cell death in EAhy926 human endothelial cells. Histol. Histopathol. 18 (2003) 715-726
22. Duerrschmidt N., Zabirnyk O., Nowicki M., Ricken A., Hmeidan F.A., Blumenauer V., Borlak J., and Spanel-Borowski K. Lectin-like oxidized low-density lipoprotein receptor-1-mediated autophagy in human granulosa cells as an alternative of programmed cell death. Endocrinology 147 (2006) 3851-3860
23. Nowicki M., Zabirnyk O., Duerrschmidt N., Borlak J., and Spanel-Borowski K. No upregulation of lectin-like oxidized low-density lipoprotein receptor-1 in serum-deprived EA.hy926 endothelial cells under oxLDL exposure, but increase in autophagy. Eur. J. Cell Biol. 86 (2007) 605-616
24. Vacca A., Ria R., Semeraro F., Merchionne F., Cosucci M., Boccarelli A., Scavelli C., Nico B., Gernone A., Battelli F., Tabilio A., Guidolin D., Petrucci M.T., Ribatti D., and Dammacco F. Endothelial cells in the bone marrow of patients with multiple myeloma. Blood 102 (2003) 3340-3348
25. Calvani M., Rapisarda A., Uranchimeg B., Shoemaker R.H., and Melillo G. Hypoxic induction of an HIF-1alpha-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells. Blood 107 (2006) 2705-2712
26. Mangieri D., Nico B., Benagiano V., De Giorgis M., Vacca A., and Ribatti D. Angiogenic activity of multiple myeloma endothelial cells in vivo in the chick embryo chorioallantoic membrane assay is associated to a down-regulation in the expression of endogenous endostatin. J. Cell. Mol. Med. 12 (2008) 1023-1028
27. Belloni D., Scabini S., Foglieni C., Veschini L., Giazzon A., Colombo B., Fulgenzi A., Helle K.B., Ferrero M.E., Corti A., and Ferrero E. The vasostatin-I fragment of chromogranin A inhibits VEGF-induced endothelial cell proliferation and migration. FASEB J. 21 (2007) 3052-3062
28. Nerini-Molteni S., Ferrarini M., Cozza S., Caligaris-Cappio F., and Sitia R. Redox homeostasis modulates the sensitivity of myeloma cells to Bortezomib. Br. J. Hematol. 141 (2008) 494-503
29. Ferrarini M., Delfanti F., Gianolini M., Rizzi C., Alfano M., Lazzarin A., and Biswas P. NF-kappa B modulates sensitivity to apoptosis, proinflammatory and migratory potential in short- versus long-term cultured human gamma delta lymphocytes. J. Immunol. 181 (2008) 5857-5864
30. Zocchi M.R., Ferrero E., Leone B.E., Rovere P., Bianchi E., Toninelli E., and Pardi R. CD31/PECAM-1-driven chemokine-independent transmigration of human T lymphocytes. Eur. J. Immunol. 26 (1996) 759-767
31. Obeng E.A., Carlson L.M., Gutman D.M., Harrington Jr. W.J., Lee K.P., and Boise L.H. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 10 (2006) 4907-4916
32. Bampton E.T.W., Goemans C.G., Niranjan D., Mizushima N., and Tolkovsky A.M. The dynamics of autophagy visualized in live cells: from autophagosome formation to fusion with endo/lysosomes. Autophagy 1 (2005) 23-36
33. Tanida I., Minematsu-Ikeguchi N., Ueno T., and Kominami E. Lysosomal turnover, but not a cellular level, of endogenous LC3 is a marker for autophagy. Autophagy 1 (2005) 84-91
34. Tafani M., Schito L., Anwar T., Indelicato M., Sale P., Di Vito M., Morgante E., Beraldi R., Makovec F., Letari O., Caselli G., Spadafora C., Pucci B., and Russo M.A. Induction of autophagic cell death by a novel molecule is increased by hypoxia. Autophagy 4 (2008) 1042-1053
35. Azad M.B., Chen Y., and Gibson S.B. Regulation of autophagy by reactive oxygen species (ROS): implications for cancer progression and treatment. Antioxid. Redox Signal. 11 (2009) 777-790
36. Matter A. Tumor angiogenesis as a therapeutic target. Drug Discov. Today 6 (2001) 1005-1024
37. Quesada A.R., Muñoz-Chápuli R., and Medina M.A. Anti-angiogenic drugs: from bench to clinical trials. Med. Res. Rev. 26 (2006) 483-530
38. Dong X., Han Z.C., and Yang R. Angiogenesis and antiangiogenic therapy in hematologic malignancies. Crit. Rev. Oncol./Hematol. 62 (2007) 105-118
39. Medina M.A., Muñoz-Chápuli R., and Quesada A.R. Challenges of antiangiogenic cancer therapy: trials and errors, and renewed hope. J. Cell Mol. Med. 11 (2007) 374-382
40. Ramakrishnan S., Nguyen T.M., Subramanian I.V., and Kelekar A. Autophagy and angiogenesis inhibition. Autophagy 3 (2007) 512-515
41. Lockshin R.A., and Zakeri Z. Apoptosis, autophagy, and more. Int. J. Biochem. Cell Biol. 36 (2004) 2405-2419
42. Bianchi G., Oliva L., Cascio P., Pengo N., Fontana F., Cerreti F., Orsi A., Pasqualetto E., Mezghrani A., Calbi V., Palladini G., Giuliani N., Anderson K.C., Sitia R., and Cenci S. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood 113 (2009) 3040-3049
43. Yorimitsu T., and Klionsky D.J. Endoplasmic reticulum stress: a new pathway to induce autophagy. Autophagy 3 (2007) 160-162
44. Fontanini A., Foti C., Potu H., Crivellato E., Maestro R., Bernardi P., Demarchi F., and Brancolini C. The isopeptidase inhibitor G5 triggers a caspase-independent necrotic death in cells resistant to apoptosis. A comparative study with the proteasome inhibitor Bortezomib. J. Biol. Chem. 284 (2009) 8369-8381